Saturday, May 9, 2026
Home Blog Page 431

USP Lays Out Guidelines For Medical Marijuana

The organization’s goal in this area is to provide suitable methods and reference standards that can help the industry and regulators ensure cannabis quality

Editors Note: This is part one of a three-part series of articles.

Good, news  U.S. Pharmacopeia (USP) lays out guidelines for medical marijuana.  The organization is bringing cannabis back into cannabis into the fold and has provided guidelines for labs and cultivators around the globe to utilize to help provide consumers with quality cannabis products.

“There is a critical and growing need for the scientific articulation of quality attributes for cannabis and related products to help protect patients and consumers from harm. As more products become available and sourced more broadly, and states continue to adopt initiatives allowing the use of cannabis for medical purposes, potential exposure to and associated risk of harm from contaminated, substandard, or super potent products is increasing and we must do what we can to mitigate that risk,” said Jaap Venema, Ph.D., Chief Science Officer at USP.

The organization’s goal in this area is to provide suitable methods and reference standards that can help the industry and regulators ensure cannabis quality, laid out in an article in the Journal of Natural ProductsCannabis Inflorescence for Medical Purposes: USP Considerations for Quality Attributes. Nomenclature is at the top of USP’s “to-do list,” an important quality attribute for labeling the ingredients, to help patients and healthcare professionals assess whether a product is suitable for particular needs.

“The thousands of so-called ‘strains’ are not consistent in either morphological or chemical profiles and cannot be relied upon for consistent categorization of different kinds of cannabis. Identity of cannabis and cannabis-derived products should be linked with clear nomenclature, including reference to plant part, product, and/or herbal preparation,” said Robin Marles, Ph.D., chair of the USP Botanical Dietary Supplements and Herbal Medicines Expert Committee.

FDA Guidance On Cannabis Research- A Glimpse Of What’s To Come For CBD Products?
Photo by Larisa Shpineva/EyeEm/Getty Images

USP has elected to recognize cannabis as a single plant species, Cannabis sativa L., with different varieties or subtypes that can be classified based on their THC and CBD content. The guidelines in the Journal of Natural Products article organize the plant into three ‘chemotype’ categories: THC-dominant, CBD-dominant, or intermediate varieties that contain physiologically meaningful levels of cannabinoids.

RELATED: Why You Didn’t Get The Cannabis Strain You Think You Did

USP is an independent, scientific, nonprofit public health organization devoted to improving health through the development of public standards for the quality, safety, and benefit of medicines and foods. The organization is comprised of over 450 academic institutions, healthcare practitioner organizations, industry groups and government representatives. USP standards are enforced by the FDA in the U.S., but since cannabis is still generally illegal under federal law, USP has not created formal compendial standards at this time. They have published a scientific paper instead of creating a conventional USP monograph. However, they still employed their rigorous process for creating the guidelines.

RELATED: Here’s Why You Have To Trust Your Dispensary

“This document is just a first step. Much remains to be learned about the clinical utility of this plant and it’s likely that future research will generate greater complexities in classification as we gain a greater understanding of its physiological effects,” said Ikhlas Khan, Ph.D., USP Cannabis Expert Panel chair.

The guidelines in the article also recommend best practices for sampling, strength and composition, and contaminant identification and limits. The hope is that they outline core quality attributes and tools that may serve as resources for quality control of the plant.

This article originally appeared on Green Market Report and has been reposted with permission.

How To Make The Holidays Feel Less Lonely This Year

0

This December marks the end of a year unlike any other in recent memory. Here’s how you can make it feel special if you’re celebrating solo.

This holiday season will be a bit unconventional, with most of us having limited options for entertaining ourselves or meeting up with friends and family. While some people have bubbled up with others, the majority of us will likely limit our social group for the season, foregoing visiting parents and grandparents in order to avoid exposing them to the unnecessary risk of COVID-19.

While this is the right thing to do, it makes for a stressful and sad holiday season, one that will be difficult to cope with for many. Here are a few simple things you can do to make the holidays feel special during the pandemic:

Fill your calendar

Photo by Flickr user Tina D

This year has been rough on relationships of all kinds. The pandemic has made it difficult for us to see each other, and when talking or texting, it leaves us in an awkward position of not having much to say. Yes, we spend most of your day indoors. There’s nothing new to discuss.

Use the holidays as an opportunity to reconnect, scheduling phone calls, Zoom chats or distanced hangouts with those that live close to you. If you haven’t talked to a friend much throughout the year, or have disagreed with their approach to the pandemic, use this time to reach out and overcome your differences.

Foster an animal

Photo by Andy Omvik via Unsplash

Animals make great companions and cuddle buddies, especially when you’re feeling lonely or sad. If you want temporary company, volunteer for walks at animal centers or ask a friend to pet sit one of their pets. If you want something for a longer period of time, look into fostering animals.

Cook something special for someone

Photo by Erol Ahmed via Unsplash

RELATED: Spending The Holidays Alone? Here’s How To Make The Most Of It

Cooking is a great distraction, one that’s soothing and time consuming, perfect for lonely holidays. What’s not great is cooking for one, which involves a lot of work and very brief enjoyment. The next time you want to cook, prepare bigger portions and give them to loved ones who live close to you. They’ll appreciate the gesture and you can use this opportunity to hang out with someone new.

Allow yourself to feel sad

5 Signs You Might Have Seasonal Depression
Photo by Dmitry Schemelev via Unsplash

RELATED: 5 Everyday Places Where COVID-19 Is Spreading

Perhaps the best thing you can do this month is to allow yourself to feel all of your emotions, happy and sad alike. The holidays are always complex, whether you spend them alone or with family. This year has been tough, and the end of it will likely result in a cathartic moment. Give yourself the room to feel it all, to reach out for help, and to get ready for the coming year. You’ll feel better.

Alternative Plant Medicine, Cannabis And Pain Management

As time goes on, alternative plant medicine, such as cannabis, are slowly changing the way pain management is viewed and executed.

Did you know that in 2019, chronic pain impacted one-third of the U.S. population? This number continues to rise which has lead to a variety of treatments tried by sufferers.  One that is gaining traction? The alternative plant medicine, cannabis and pain management.

Currently, different NSAIDs (non-steroidal anti-inflammatory drugs), acetaminophen, and opioids are used the most often for the treatment of pain. However, there’s no guarantee that these drugs will be fully effective in eliminating pain nor is there a guarantee that these drugs won’t cause any adverse side effects.

Nowadays, cannabis and its many cannabinoids are being pursued more because of their medicinal and therapeutic properties.Overall, though, alternative plant medicine is becoming a part of thousands of people’s routines and lifestyles for numerous reasons. Here are a few main reasons why.

Understanding Types of Pain and How to Treat It Properly

Oftentimes, when someone experiences pain, their primary mission is to eliminate it and use or consume a product to achieve relief. Before treating pain though, it’s important to understand the characteristics of the pain itself, the severity of it, and the nature of it. For example, is the pain acute or chronic? Is it neuropathic or inflammatory pain? Is the pain caused by an injury, illness, ailment, or a new medication? After understanding the type of pain, finding an appropriate treatment method is the next step.

RELATED: What We Can Learn About Cannabis From Chinese Medicine

When evaluating numerous treatment methods, it’s essential to understand the efficacies of different treatment options and potential adverse effects/reactions. From here, an individual should be able to find a suitable treatment method that aligns with the type of pain they’re experiencing.

Traditional Medicines Versus Alternative Plant Medicines

Although opioids, NSAIDs, acetaminophen, and various OTC (over-the-counter) drugs tend to be the norm for pain management and/or relief, cannabis and its array of beneficial cannabinoids are growing in demand and usage.

Specifically, to avoid potential adverse side effects and/or the risk of drug addiction or dependency, for many, opioids are taking a back seat, and cannabinoids are being pursued instead. Despite traditional medicines demonstrating their efficacy in many different situations and among different people, issues can still arise post-consumption.

RELATED: More Women Switch Out Pharmaceuticals For Medical Marijuana

For example, NSAIDs can be beneficial, but they’ve also been associated with severe complications involving the gastrointestinal, cardiovascular, and renal systems. Next are opioids, which have proven their effectiveness in different situations, but they’ve also demonstrated their ability to cause cognitive deficiencies, motor impairment, and respiratory depression. Opioids also unfortunately represent a substantial addiction and dependency risk among specific groups of individuals.

As time goes on, alternative plant medicine, such as cannabis, numerous cannabinoids, and terpenes, are slowly changing the way pain management is viewed and/or executed.

Israeli Firm Says Medical Marijuana Best Taken In Microdosing Format
Photo by Esther Kelleter/EyeEm/Getty Images

Cannabis For Pain Management & Treatment

The cannabis plant contains over 100 cannabinoids, but some of them are more well-known such as Cannabidiol (CBD) and Tetrahydrocannabinol (THC). Numerous cannabinoids are medically and therapeutically beneficial in multiple ways, but CBD, THC, Cannabichromene (CBC), and Cannabigerol’s (CBG) analgesic properties stand out. So far, it has been found that CBC contains both anti-inflammatory and analgesic properties. Whereas, CBG has proven its stronger analgesic activity than THC. 

Aside from different cannabinoids’ analgesic properties, various terpenes found on the cannabis plant are analgesics as well, especially myrcene. One 2008 study expanded on this and stated that: “Myrcene is analgesic, and such activity, in contrast to cannabinoids, is blocked by naloxone suggesting an opioid-like mechanism.” Another terpene that contains analgesic and anti-inflammatory attributes is β-caryophyllene.

RELATED: Why Cannabis Is Better Than Opioids

In addition, cannabinoid analgesics have generally been well-tolerated within clinical trials. The World Health Organization (WHO) also reported that CBD is non-psychoactive, non-toxic, non-addictive, and has a good safety profile.

Although there’s more to learn about cannabinoids and pain management, various surveys of cannabis users have shed light on the substitution of cannabis products for opioids. Specifically, one 2017 survey focused on American and Canadian cannabis users, and the following was reported: “Our findings are consistent with prior surveys of American and Canadian marijuana users in which substitution of marijuana for opioids was prevalent due to better symptom management and fewer adverse and withdrawal effects.”  

How To Do Your Part In Advancing Cannabis Reform In Your State

0

With much to fight for, marijuana advocates say that people can and should do their part however possible. Here’s how.

Cannabis reform continues to make progress in America. With several states passing legislation on Election Day, and several more on the verge of doing the same soon, some may think that the fight is winding down. That isn’t the case when talking to those involved in the movement.

While much of the decades-long heavy lifting to earn back the public’s support for cannabis is already complete, there is much more to get done. Be it legalization or other policy reforms, advocates across the U.S. can and should still get involved in the fight. Even the most progressive of states continue to suffer pain points that advocates hope to address in a bid to create a fair and equal market for patients, consumers, marginalized communities and everyone else in the space. 

Jordan Isenstadt is the senior vice president of New York-based PR firm Marino. Isenstadt, who has worked in the administration of several New York State Senators and the Governor, spoke about the importance of advocacy in the community. He calls cannabis reform “one of the great social challenges of our time.” 

Isenstadt described the previous century of cannabis policy as failed and racist. “Being an advocate for cannabis today is about righting the wrongs of a century of failed policymaking,” said Isenstadt. He added, “Cannabis advocates have an opportunity to make history over the next few years.”

Wanda James, a career advocate and entrepreneur in and out of cannabis, said that advocacy remains essential because the goal has not been reached–particularly inclusion efforts.

James, CEO of Simply Pure Dispensary and president of the Cannabis Global Initiative, points to the ongoing racial disparity that spans American life, affecting Black and other minority groups at staggering rates. “The only way that we’re going to change how people talk about cannabis is when we fully legalize it,” added James. 

Sources say that advocates are needed in other areas as well, including patient rights. Marijuana Policy Project Director of Government Relations Chris Lindsey noted that medical patients often face steeper challenges as states legalize adult use. 

Lindsey elaborated, saying that advocates help keep the moral compass oriented. “With the huge amount of attention legalization gets from many different groups and agencies, the voice for individuals who rely on these programs for access to medicine shouldn’t be drowned out,” said Lindsey. 

With much to fight for, advocates say that people can and should do their part however possible. 

A Dozen Governors Urge Congress To Pass Marijuana STATES Act
Photo by rawpixel.com

How To Get Involved In Cannabis Advocacy—Even If You Don’t Have The Time

Cannabis advocacy can become a large component of someone’s life just as much as it can become a small part of their day. Either way, sources say these efforts can amount to continued progress.

There appears to be no clear-cut first steps a person should take to become an advocate–mostly because anyone can do their part at just about anytime. 

Simply Pure’s James said the first step a person should do is normalize cannabis conversations and use, as long as the person isn’t risking their job in the process. Essentially, work the plant into everyday conversations and continue with daily practices, like swapping out an end-of-night glass of wine with your partner to a joint.

RELATED: How the Georgia Runoffs Could Shape Cannabis Reform

The cannabis leader then recommends contacting local officials as another quick and effective step. James said advocates could leave a message stating their support for specific measures, giving a brief reason why to back their claim. 

“These conversations and these actions are so simple that we can do,” said James.

Marino’s Isenstadt said education is paramount–suggesting people learn about key stakeholders, regulators, elected officials and other prominent members in the space as a first step.  

A Right-Leaning Supreme Court Won't Impede Cannabis Reform, Legal Experts Say
Photo by Esther Kelleter/Getty Images

From there, would-be advocates can get involved with various advocacy groups. He noted that groups typically consist of various central issues, including pro-business groups that represent large multi-state operators and grassroots advocates for small businesses, farmers, healthcare, social justice and other pressing matters.  

RELATED: A Right-Leaning Supreme Court Won’t Impede Cannabis Reform, Legal Experts Say

“Figure out which organization(s) speaks most to you and look for ways to get engaged,” said Isenstadt. 

James highlighted groups like NORML, Minorities for Medical Marijuana and Women Grow as three organizations advocates should look into. 

RELATED: Why A Biden-Appointed, Pro-Cannabis Attorney General Is Important For Weed Reform 

Isenstadt added that scores of organizations have volunteer and advocacy activities, including virtual events, fundraisers, letter writing and phone to action campaigns. Currently, these events are all virtual. When in-person meetings become the norm again, advocacy events can also help advocates become further ingrained in the fight and the cannabis community by making face-to-face connections.

Isenstadt added that those short on time could make cash donations if they are in the financial position to do so. “It only takes a few minutes to give money, and many of the advocates, especially those fighting for social justice reform, could use the funds.”

Science Confirms Cannabis Combats Cancer

While not sufficient treatment in itself, research continues to find cannabis is an excellent tool in the war against cancer.  

In a recent study, Thomas M. Clark, Ph.D., head of a recent analysis, found that “the anticancer effects of cannabis outweigh the carcinogenic effects even in the airways and bladder, where carcinogen exposure is high.”  This is another example where science confirms cannabis combats cancer.

Clark headed anAugust analysisdirectly on the issue of cannabis and cancer, supported by his sabbatical leave from Indiana University South Bend. At first, Clark had three hypotheses: cannabis increases cancer risk, the benefits and risks of using cannabis canceled out, or cannabis lowers cancer risk. 

At the first analysis of the data set, there was a slight association with cannabis and reduced cancer risk. However, by removing data that did not control for tobacco use, defined as data with a high risk for selection bias, and data at risk for performance bias, the association became medium to large. 

Likewise, the data revealed a medium to large association with reduced cancer risk if data related to testicular cancer was removed. However, according to the analysis, “the hypothesis thatcannabisuse increases cancer risk is not supported by the available data.” 

Making Sense of the Complexity of Cancer Risk 

In the words of Clark, “decreased cancer risk incannabisusers should not be surprising, ascannabisand cannabinoids decrease obesity, inhibit chronic inflammation, reduce fasting insulin levels and insulin sensitivity, and have direct antitumor actions.” 

The Incredible Truth About Marijuana And Bladder Cancer
Photo by Sezeryadigar/Getty Images

The effects cannabis has in fighting obesity are far-reaching and severe. Research on amouse modelfound that not only did THC treatment prevent obesity, but it preserved the gut microbial flora, preventing it from mirroring an obese phenotype. 

RELATED: House Approves Bill To Enhance Medical Marijuana Research

Additionally, cannabis lowers insulin resistance and can act as an anti-inflammatory.Researchhas proven cannabis’s anti-tumor effects in a laboratory setting. 

According to Clark’s math, cannabis may decrease the risk of cancer by 10%. If that is true, then among the 55 million Americans cannabis users, the substance may prevent as many as 23,800 to 35,700 cancer diagnoses and 8,498 to 12,747 cancer deaths each year.  

While not sufficient treatment in itself, research continues to find cannabis is an excellent tool in the war against cancer.  

DEA Hit With Another Lawsuit Scientists About Cannabis

The time is nigh for the DEA to cooperate in ensuring that medical marijuana research can move forward. Finally.

On December 3, 2020, MAPS (the Multidisciplinary Association for Psychedelic Studies) issued a press release regarding a lawsuit filed against the DEA and the Attorney General to “compel issuance of licenses to manufacture marijuana for clinical trials and potential FDA approval.” We have written about MAPS and its 35 years of advocacy and engagement with DEA before, and we are big fans of the nonprofit.

The announcement of this lawsuit comes on the heels of the United Nations Commission for Narcotic Drugs (CND) voting to accept the World Health Organization’s (WHO) recommendation to remove cannabis and cannabis resin for medicinal purposes from Schedule IV of the 1961 Single Convention on Narcotic Drugs. The U.S. had already confirmed it would support the WHO recommendation and published a statement about its rationale for the vote:

“The vote of the United States to remove cannabis and cannabis resin from Schedule IV of the Single Convention while retaining them in Schedule I is consistent with the science demonstrating that while a safe and effective cannabis-derived therapeutic has been developed, cannabis itself continues to pose significant risks to public health and should continue to be controlled under the international drug control conventions. Further, this action has the potential to stimulate global research into the therapeutic potential and public health effects of cannabis, and to attract additional investigators to the field, including those who may have been deterred by the Schedule IV status of cannabis.”  

In MAPS’ announcement of the lawsuit, it points out that “[e]fforts to conduct meaningful research into cannabis medicines have been blocked for decades; the continued obstruction is causing suffering for people with serious conditions,” which indicates the timeliness of this lawsuit in relation to the CND’s recent vote. According to MAPS and the lawsuit, the DEA has failed to process more than thirty outstanding applications to develop cannabis for research purposes for more than four years despite administrative guidance. The press release outlines the nature of the lawsuit as follows:

“Nearly 20 years after Dr. Lyle Craker of the University of Massachusetts – Amherst first applied for a license to develop a consistent, reliable pharmaceutical cannabis product to address the needs of patients with serious illnesses. Despite broad public support for legal, regulated access to medical marijuana, as well as new DEA policy pronouncements and an opinion by the U.S. Department of Justice that the Agency refused to publicly disclose, the DEA has continued to prevent the processing of license applications in violation of the Administrative Procedures Act and contravention of its own administrative guidance. Dr. Craker, supported by the Multidisciplinary Association for Psychedelic Studies (MAPS), has filed a lawsuit in the U.S. District Court in Massachusetts to compel the Drug Enforcement Administration (DEA) to end their delay and process marijuana producer and manufacturer license applications thereby allowing sanctioned scientific research toward a viable medical cannabis pharmaceutical product to proceed.”

House Approves Bill To Enhance Medical Marijuana Research
Photo by CasarsaGuru/Getty Images

Under the Controlled Substances Act (CSA), manufacturers of all Schedule I controlled substances, including marijuana, must be licensed by the DEA. Currently, and since 1968, the only federal license issued to provide cannabis for clinical research purposes belongs to the University of Mississippi and is supervised by the National Institute on Drug Abuse (NIDA).

RELATED: House Approves Bill To Enhance Medical Marijuana Research

According to the lawsuit, and widely discussed opinion throughout the industry, the marijuana provided by the University of Mississippi and NIDA is unfit for clinical research due to “poor quality, unstable supply, and limited variability that in no way emulates the types of cannabis currently available through either state-regulated markets or informal markets where regulated supply is unavailable.”

In addition, this limited, poor quality supply of marijuana is only for permitted use in research and not in commercial sales, meaning it cannot be used in FDA-regulated Phase 3 studies which must be conducted with the exact drug, manufactured under Good Manufacturing Processes, that would be marketed.

RELATED: ICYMI: DEA And Cannabis Research Still Lousy Bedfellows

The goal in compelling the DEA to process these outstanding license applications is to allow for additional research into the potential medical benefits and uses of marijuana – something that in the U.S. has undeniably become an issue with bi-partisan support, yet remains mindbogglingly difficult to achieve through government channels. The results of the November election approving cannabis legalization measures across the board in the U.S., coupled with the CND’s vote to remove medicinal cannabis from Schedule IV, indicates that the time is nigh for the DEA to cooperate in ensuring that medical marijuana research can move forward. Finally.

Alison Malsbury is co-chair of Harris Bricken’s corporate practice group and focuses her practice on health and wellness, in addition to corporate and intellectual property transactions, working primarily with our cannabis, tech and entertainment clients. 

This story was originally published on the Canna Law Blog.

Does Eminem Consume Weed

This year, Eminem released a record and a surprise LP. He’s been very open about his drug use in the past. Does he smoke weed?

Like what many artists are doing nowadays, Eminem has released some surprise music for his fans. He just dropped a companion LP to his 11th studio album, Music To Be Murdered By, which was released back in January.

While the drop was a surprise, clues began circulating at the beginning of the week, with several of Eminem’s collaborators releasing Twitter and Instagram images of cover art and track lists. Music To Be Murdered By Side B marks Eminem’s third surprise release in his career.

Does he smoke weed?

Eminem has been open about his struggles with drug addiction in the past, writing many songs on the topic and not shying away from sharing personal milestones with fans. While recovering addicts sometimes smoke marijuana, every person’s relationship with drugs is personal.

 

View this post on Instagram

 

A post shared by Marshall Mathers (@eminem)

Eminem has revealed that his problem with addiction began in his mid-20s when he started taking prescription drugs. “It was easy in the beginning,” he said. “I didn’t have the money to get really involved in drugs. I’d do them when somebody offered them to me. As my career took off and the crowds got larger and life got faster, I reached out for that sh– more and more. I used it as a crutch to calm my nerves. Especially the sleeping pills.”

RELATED: Legendary Rapper Redman On The Fight For Cannabis Legalization, The Gateway Myth, Parenting And Pot

This period in his life was followed by a four-year hiatus from music, where he spent his time in rehab and then relapsed. The release of his album Recovery marked the time when he was clean from drugs, a time which he refers to as happy and creatively fulfilling.

When it comes to weed, there’s not a lot of information out there except for what’s in Eminem’s songs. His most prominent weed song, Must Be The Ganja, is your standard rapper drug song, one that doesn’t say much about his personal relationship with it. In The Adventures of Moon Man and Slim Shady, a song in which he collaborated with Kid Cudi, he says: “I had hoop dreams, now I shoot threes, Got a lil’ green, but I don’t do weed.”

RELATED: Does The Weeknd Smoke Weed?

These are all just songs though. Unless Eminem makes a public statement or is seen smoking weed openly, there’s no way of knowing whether he uses marijuana or not.

Recreational Cannabis Could Show Up In New Jersey Within 6 Months

Reports estimate that just 37 recreational cannabis licenses will be available. More licenses are not expected to be released for another two years.

By Anthony Noto

New Jersey lawmakers have passed a measure to allow a recreational marijuana marketplace in the Garden State.

The legislation will now be sent to Democratic Gov. Phil Murphy, who is expected to sign the bill. Once that happens, New Jersey cannabis businesses will be able to offer recreational weed within six months.

The Democrat-led Assembly and Senate passed the bill on Thursday.

The six-month time frame would be among the shortest wait times from legalization to “market open date” for a recreational cannabis state. In Massachusetts, it took over two years from the time a similar measure was approved to the opening of the state’s first cannabis dispensaries. Nevada took eight months.

Maine, the first to open the adult-use market in New England, had the longest wait: 47 months.

The quick turnaround in New Jersey bodes well for several cannabis players, including Curaleaf Holdings Inc. CURLF 4.41%Acreage Holdings Inc. ACRDF -1.50%Green Thumb Industries Inc. GTBIF 0.33%TerrAscend Corp. TRSSF -0.27% and Columbia Care Inc. CCHWF -1.19%. Each company has expressed plans to expand across the state.

Last month, most New Jersey voters supported recreational cannabis in a ballot measure on Election Day. Over 67% of the respondents voted in favor of legalizing marijuana, while almost 33% voted against it.

The move was praised by reform advocates as a necessary step to stop what NORML National estimates to 32,000 cannabis arrests per year.

RELATED: Atlantic City Casinos Will Probably Continue To Ban Marijuana

New Jersey voters also approved a 6.625% state tax on cannabis sales to customers aged 21 or older and permitted municipalities to charge an extra 2% tax. The measure is reportedly expected to rake in $126 million a year for New Jersey once the market is settled.

New Jersey Gov: Extremely smart to legalize marijuana to offset coronavirus pandemic
Photo by Howard Kingsnorth/Getty Images

Cannabis research firm Brightfield Group expects cannabis sales to reach about $460 million in 2021 and $1.5 billion by 2025.

RELATED: New Jersey Legalized Recreational Cannabis — Now What?

Whether smaller businesses will be granted recreational licenses remains to be seen. New Jersey’s cannabis entrepreneurs, not affiliated with publicly traded companies, have been urging Gov. Murphy to not overlook small businesses and grant recreational cannabis licenses without the burden of an exorbitant fee.

Currently, there will be a limited number of licenses available. Reports estimate that just 37 will be available. More licenses aren’t expected to be released for another two years.

This article originally appeared on Benzinga and has been reposted with permission.

Harry And Meghan Blew Chance At Happy Royal Life

0

Meghan Markle and Prince Harry had the world at their feet, according to one royal insider. But is the Duchess of Sussex to blame for the royal family fallout?

The Duke and Duchess of Sussex “had their world as their oyster” according to the Queen’s former press secretary Dickie Arbiter. But Harry and Meghan blew chance at a happy royal life.

Arbiter made those remarks on a British TV series called “The Royal Beat,” while also stating that before he met Meghan, Prince Harry had accepted his role as the “spare” to his brother William’s “heir,” but then Meghan became sulky.

“Their world was their oyster and they blew it. They literally blew it, they had everything [but] I don’t think everything was what Meghan wanted,” Arbiter told host Kate Thornton.

“Harry was the spare and the Cambridges are the heirs.

“He accepted his role, he was always born to that.

“Until Meghan came along and she could not accept that. She couldn’t accept being in the second row.”

RELATED: Former Royal Butler Spills Tea On Queen’s Falling Out With Prince Harry

He added that “Harry’s biggest mistake was leaving the army. He should have never left.”

Royal commentator and executive editor of The Sun, Dan Wootton, echoed Arbiter’s sentiments, adding that although the Duchess may not be solely responsible for the falling out with the royal family, she seems to “fall out” with just about everyone else she’s close to.

This Is What Princes William And Harry Were Almost Named
Photo by Chris Jackson/Staff/Getty Images

“She falls out with virtually anyone who she’s close to, including her own blood relatives,” he said.

“So it’s not a surprise that she engineered a split between Harry and the people he has been the closest to and relied on for his whole life.

RELATED: Kate And William Have Changed In This Major Way Since Meghan And Harry Left

“He was so close to William and so close to Kate.

“Now, I’m not saying that you can blame Meghan specifically for the breakdown in that relationship.

“I think both couples rubbed each other up the wrong way from the start.”

As to why Meghan and Harry stepped away from their royal duties and moved to California (aka Megxit), royal expert Katie Nicholl said it had everything to do with money.

“I think it was to have latitude, to have space, but ultimately it was to make money and that is what they are doing.”

Harry And Meghan blew chance at happy royal life, no surprise.

Kentucky Governor Urges Lawmakers To Legalize Marijuana

Last year, Gov. Beshear told the press that he believes medical marijuana is essential for Kentucky, especially for those suffering from chronic pain.

Bluegrass state Governor Andy Beshear wants state lawmakers to get serious about legalizing medical marijuana in 2021. This week, in a virtual address, the Bluegrass State’s head chief urged the upcoming General Assembly not to get bogged down by politics. He wants the House and Senate to find a compromise on this issue so that the state can finally begin to serve patients in need. To be clear, Kentucky Governor urges lawmakers to legalize marijuana.

State lawmakers have been fighting over medical marijuana for the past several years. It’s an issue that has found some success in the House but always seems to get squashed the second it lands in the Senate. 

Earlier this year, Beshear broke the vote on a bill in the House aimed at legalizing marijuana for medicinal use, but the Senate wasn’t having it. In fact, while Senate President Robert Stivers promised House lawmakers a “fair chance,” the upper chamber never even gave the bill a hearing. The governor wants this attitude to change. He is calling for a more unified front in the new year.

“We need to come together and not create unnecessary political fights that are going to squander time and energy, leaving us mad and frustrated,” Beshear said. 

Representative Jason Nemes is getting the ball rolling. He plans to reintroduce a bill very soon designed to legalize medical marijuana. It’s identical to the one that was ignored by the Senate earlier this year. And while some believe the measure is too restrictive (it doesn’t allow smoking, home grows, and there is enormous oversight on every facet of the program), lawmakers feel that is what makes it one of the best pieces of medical marijuana legislation in the country.

And the House is all for it. 

“The support in the House will be even stronger than it was last year,” Nemes told the Messenger-Inquirer. “We have replaced a number of ‘no’ votes with ‘yes’ votes in the Republican caucus due to retirement and defeating Democrats, so we will be stronger in the House. The whole question is what the Senate will do.”

Well, what will it do? 

There’s a good chance the answer is: not much. When ABC-affiliate WHAS-11 asked Stivers about the prospect of the Senate voting on medical marijuana next year, he shrugged it off, saying the bill hasn’t even been approved yet in the House. But if it does cross his desk at some point in 2021, “I’m going to reiterate that we’re going to focus on a lot of the issues that we feel we need to do.”

Translation: Medical marijuana isn’t going to be a priority.

RNC Head Refuses To Answer Whether GOP Welcomes Medical Marijuana Supporters
Photo by thegoodphoto/Getty Images 

Kentucky cannabis advocates understand this, and they are not optimistic about the bill being treated fairly or given any consideration in the new year. Dan Seum, Jr., son of former Kentucky Senator Dan Seum Sr., says the bill is doomed. “I vote Republican, but I’m ashamed of the leadership there. They’re not going to let it go unless we put so much pressure on them,” he told WHAS-11. 

RELATED: Kentucky’s Medical Marijuana Would Be Tightly Regulated

However, Representative Nemes believes that if Stivers would just allow the medical marijuana bill to go before the upper chamber, it would receive the support it needs to land on Governor Beshear’s desk.   

“If it comes to a vote in the Senate, I am confident that it will pass,” he said. “I think the votes are there. I have been told many times over the years fighting for this bill that it would never get a vote in the House, and if it did, it wouldn’t pass. Well, I got 2/3 of the House and will have over that this year and I don’t have any reason to believe that those numbers won’t be similar in the Senate.”

RELATED: Which State Will Legalize Marijuana First In 2020: Kentucky, Ohio Or Indiana?

If by some miracle the bill collects all the support it needs to make it out of the General Assembly, rest assured the governor will be eagerly waiting to make it law. Last year, Beshear told the press that he believes medical marijuana is essential for Kentucky, especially for those suffering from chronic pain.

Don't Miss Your Weekly Dose of The Fresh Toast.

Stay informed with exclusive news briefs delivered directly to your inbox every Friday.

We respect your privacy. Unsubscribe anytime.